COPENHAGEN, Denmark, Aug. 30, 2023 /PRNewswire/ -- Embark Laboratories announced today that Novo Nordisk has acquired Embark Biotech, including its lead metabolic program, and has entered a three-year ...

Wegovy maker Novo Nordisk (NVO) agreed to buy Embark Biotech for €15 million ($16 million) in cash upfront, in a move that could boost Novo Nordisk's portfolio of weight loss treatments. In addition, ...

Novo Nordisk is already an obesity drug heavyweight with its blockbuster seller Wegovy, but its appetite for cardiometabolic drugs continues. The Danish pharmaceutical giant is satisfying that hunger ...

Novo Nordisk’s hot buying streak continues as it adds another obesity biotech through its acquisition of Embark Laboratories, announced Wednesday. The deal, worth about $16 million upfront and up to ...

Mirum Pharmaceuticals (MIRM) is a good speculative biotech play to look into. The reason why I state that is because it has already received FDA approval for a drug from its pipeline. It received ...

Novo Nordisk A/S (NYSE:NVO) continues to bolster its obesity portfolio. In the latest move, the Danish pharma giant has acquired Embark Biotech. Novo Nordisk will pay upfront of €15 million, and ...

The positions in the table below reflect the Embark Biotech ApS's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

Article ‘Count’ and ‘Share’ for Embark Biotech ApS based on listed parameters only. The articles listed below published by authors from Embark Biotech ApS, organized by journal and article, represent ...